Product Images Aripiprazole

This text provides information on the effects of different drugs on the pharmacokinetics of aripiprazole. It includes details such as the effect of CYP3A4 Inhibitor (ketoconazole), CYP2D6 Inhibitor (quinidine), CYP3A4 Inducer (carbamazepine), Gastric Acid Blockers (famidine), and other drugs like valproate, lithium, and lorazepam. The text also mentions the Aripiprazole Fold Change and 90% CI, showing the relative change in aripiprazole levels when interacting with these different drugs. This information is valuable for understanding potential drug interactions and their impact on aripiprazole metabolism.*

Not available*

This text provides information on the effects of aripiprazole on the pharmacokinetics of other drugs. It includes a chart with data on the fold change and 50% confidence interval for various drugs when interacting with aripiprazole. The drugs mentioned in the text include deropmetoptan, cvpace, artann, svartain, omeprazole, lamotigine, valproate, lithium, lorazepam, venlafaine, desmyhenataing, and escitiopram. The chart also shows the change relative to a reference (without interacting drug).*

This is a description of the effects of intrinsic factors on aripiprazole pharmacokinetics in special populations. The text includes comparisons of AUC and Cmax in terms of different factors such as CYP2D6 metabolizer status, gender, age, hepatic impairment levels, and renal impairment levels. The data presented in the figure show fold change and 90% confidence interval for these comparisons.*

This text provides a table showing the effects of intrinsic factors on dehydro-aripiprazole pharmacokinetics. The factors evaluated include CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and renal impairment severity. Data is presented in terms of fold change and 90% confidence intervals for AUC and Cmax. The comparison groups are poor vs. extensive metabolizers, female vs. male gender, 18 to 64 vs. 65 years old age group, mild vs. normal hepatic function, and different levels of renal impairment.*

This text provides information about the proportion of patients experiencing relapse in a schizophrenia study comparing Aripiprazole to Placebo. The data includes a Kaplan-Meier Estimation of cumulative proportion over time and shows the number of subjects at risk in each group. The chart displays the progression of relapse in patients over days from randomization.*

This is a partial data extract from Figure 7 of a study related to the Kaplan-Meier estimation showing the cumulative proportion of patients with relapse, specifically for Bipolar Study 7. The data includes the number of subjects at risk for both the Aripiprazole and Placebo groups at various time points measured in days from randomization.*

This is a Kaplan-Meier estimation chart showing the cumulative proportion of patients experiencing relapse to any mood event in Bipolar Study 8. The graph includes data points for ABILIFY on day 168 and LACE on day 169.*

This is a description of a packaging for Abilify 20mg Tablet by Torrent Pharmaceuticals Ltd. It comes in a pack of 30 tablets with an expiration date. The tablets are to be stored at room temperature. The package also includes safety instructions to keep all drugs out of reach of children. The NDC number is 7133504121.*